

Asymptomatic severe mitral regurgitation in patient with undifferentiated connective tissue dysplasia. Clinical case of timely diagnosis and successful treatment

Martyanova Yu.B.¹, Chernysheva E.N.², Kondratyev D.A.¹, Lyalyukova E.A.³

¹ Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia, Astrakhan, Russia.

² Astrakhan State Medical University of the Ministry of Health of Russia, Astrakhan, Russia.

³ State Medical University of the Ministry of Health of Russia, Omsk, Russia.

AUTHORS

Yulia B. Martyanova*, MD, cardiologist of the Department of Cardiac Surgery No. 1 of the Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia, Astrakhan, Russia.

Elena N. Chernysheva, MD, PhD, docent, head of the Department of Cardiology of the Astrakhan State Medical University of the Ministry of Health of Russia, Astrakhan, Russia.

Dmitry A. Kondratyev, MD, PhD, head of the Department of Cardiac Surgery No. 1 of the Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia, Astrakhan, Russia.

Elena A. Lyalyukova, MD, PhD, docent, professor of the Omsk State Medical University of the Ministry of Health of Russia, Omsk, Russia.

Abstract. The spectrum of mitral valve (MV) pathology in patients with connective tissue dysplasia (CTD) include conditions from myxomatous degeneration with excess tissue of the valve leaflets and subvalvular apparatus, which is more common among young patients, to fibro-elastic deficiency of the MV leaflets that is usually diagnosed in older age groups. Mitral regurgitation (MR) in patients with dysplasia belongs to the category of primary MR that can progress and lead to surgical treatment. It is known that surgical intervention on MV in patients with CTD is recommended in cases of symptomatic severe MR. In asymptomatic severe MR with such patho-

physiological consequences as left ventricular systolic dysfunction, pulmonary hypertension, atrial fibrillation, surgical treatment is also indicated. The question of surgical treatment of asymptomatic severe MR without the mentioned above criteria remains controversial. Using the clinical example of long-term observation of the asymptomatic severe MR we will present step-by-step algorithm for patients with severe primary MR considering the latest clinical guidelines on valvular heart disease of 2021.

Keywords: mitral valve, mitral regurgitation, mitral valve repair, mitral valve replacement, mitral valve dysplasia.

* Corresponding author. Tel. +7 (937) 828-4885. E-mail: martyanova911@mail.ru

Conflict of interest: none declared

Received: 25.09.2022

Accepted: 24.11.2022



For citation: Martyanova Y.B., Chernyshova E.N., Kondratyev D.A., Lyalyukova E.A. Asymptomatic severe mitral insufficiency with the background of undifferentiated connective tissue dysplasia syndrome. Clinical case of timely diagnosis and successful treatment. 2022; 10(36): 42-47. doi: 10.24412/2311-1623-2022-36-50-56

Introduction

Primary MR is associated with pathology of the MV and/or its subvalvular structures in contrast to secondary MR due to left ventricular (LV) pathology or left atrial dilatation (LAD) in patients with atrial fibrillation (AF). The most common cause of primary MR is connective tissue dysplasia, known as MV prolapse (MVP), a degenerative MV disease. Cardiac auscultation and echocardiography are the main tools for the diagnosis of this pathology, accompanied by transesophageal echocardiography (TEE) and cardiac MRI in controversial cases.

The understanding of disease pathophysiology and timely use of effective MR surgery is essential for the management of patients with severe primary MR. The necessity of surgical treatment is assessed considering the severity of MR, size and function of LV, presence of pulmonary hypertension (PH), AF, correction possibilities by MV repair, and of course, disease symptoms. In the absence of complaints in patients with severe primary MR, it is difficult to decide whether to perform surgery or wait, and waiting will sooner or later lead to irreversible left ventricular dysfunction.

Rational management of such patients is based on the research data that are used to update the clinical guidelines for the management of valvular heart disease regularly.

Clinical case

Patient Ya., 36 years old. Heart murmur persisted since the age of 15, at the age of 18 he was diagnosed with severe MR in the background of MV prolapse. The patient had been annually observed for 10 years, but because of the absence of complaints and stable normal parameters according to echocardiography, he did not consult a physician afterwards. Over the last year he started to have increased heart rate (HR) at rest that was the urged him to cardiologist.

The patient had asthenic constitution (height 186 cm, weight 71 kg, BMI 20.5); auscultation revealed holosystolic murmur in the precardiac area within in-

terscapular space. Cardiac rhythm was regular, apex beat was intensified. Six-minute walk test — 500 meters. ECG showed sinus rhythm, signs of left ventricular (LV) myocardial hypertrophy.

To determine the strategy for management of MVP, it is necessary to confirm the clinical and auscultatory picture by visualization of the heart valves.

Echocardiography is a gold standard for the diagnostics of cardiac valve pathology [1, 2]; in case of MR it enables to estimate its presence and severity accurately, describe MV pathology (changes of leaflets, localization, mechanism of MR — tear or prolapse, etc), determine hemodynamic consequences of heart chambers volume overload. In controversial cases, echocardiography can be supplemented by stress echocardiography, transesophageal echocardiogram (TEE), cardiac magnetic resonance imaging (MRI) and cardiac computed tomography (CT) [3, 4].

Step-by-step follow-up of the clinical guidelines for the management of valvular heart disease helps a physician to identify MR, determine the stage of the disease and, based on the results of scientific research, improve long-term outcomes in asymptomatic patients with severe MR [5, 6], by choosing the optimal and well-timed treatment strategy.

Step 1: Assessment of MR severity is performed according to the criteria proposed by ACC/AHA [7, 8]. MR is defined by both qualitative and quantitative criteria. Criteria of MR, including severe, are presented in Table 1.

Step 2: Determination of etiology and mechanism of MR. In primary MR, the most frequent etiological cause is MVP (about 2% in the population) [9, 10]. The important point is to specify: whether one or both leaflets are affected, whether there is no rupture of subvalvular structures.

At this stage it is also essential to clarify whether the primary MR was due to fibroelastic deficiency, as in isolated MV prolapse, or is it the Barlow disease, when there is an excess of MV tissue. The later situation is considered in the case of both leaflets prolapse

Table 1. MR severity criteria

	Severity	Mild	Moderate	Severe
Qualitative criteria	Assessment by coronary angiography	1+	2+	3–4+
	Color flow doppler	< 20 % LA	Variable	Central > 40 % LA or holosystolic eccentric flow through MV
Quantitative criteria	Vena Contracta	< 0,3 cm	0,3–0,69 cm	≥ 0,7 cm
	Regurgitation volume, (ml/beat) RegVol	< 30	30–44 45–54	≥ 60
	Regurgitation fraction RF (%)	< 30	30–39 40–49	≥ 50
	Effective regurgitant orifice area ERO (cm ²)	< 0,2	0,2–0,39	≥ 0,40

that will be important for subsequent surgical treatment of MR.

Step 3. Evaluation of cardiac chamber sizes and volumes, LV function, which change under the influence of volume overload due to severe MR [11, 12].

Step 4. Assessment of the disease stage (Table 2). At this point, it is important to determine the stage of the disease, since the patient, remaining asymptomatic in stage C (see Table 2), has compensated MR, and MV surgery can still improve patient's prognosis. In urgent stage D, MR correction is usually ineffective [13, 14].

What is known about prognosis of asymptomatic patients with severe primary MR? The chance of asymptomatic patient with severe MR not to have chronic heart failure (CHF) and AF within 5 years is 36 % [15]; 30–40 % of patients will need MV surgery within 5 years, and complications they will include CHF, AF, pulmonary hypertension (PH), stroke, ventricular tachycardia/ventricular fibrillation (VT/VF), death. Non-operative mortality in asymptomatic patients with primary MR is 0–8.4 % [15, 16].

There are data on outcomes and various markers in patients with asymptomatic severe primary MR:

Assessment of MR and ejection fraction (EF) has a great prognostic value. According to Enriquez-Serrano

group, the more severe is the MR, the worse is the prognosis [17, 18]. In MR, left ventricular ejection fraction (LV EF) is "supernormal", i.e., EF over 60 % is considered normal, and below 60 % — below normal and should be a trigger for surgical intervention.

In a multi-centric study, Ling et al. demonstrated that MV subvalvular rupture is always characterized by worse prognosis than in a healthy population, and outcomes with early surgery are superior to medical treatment [19, 20].

Patients with severe primary MR accompanied by PH had worselong-term outcomes— pulmonary artery pressure (SPAP) less than 35 mm Hg did not affect the prognosis, and when it increased over 45 mm Hg, the long-term prognosis worsened [21, 22].

Additional markers in patients with severe MR — LV Strain and brain natriuretic peptide (BNP) [23, 24]. In the study of 548 asymptomatic patients with severe MR and preserved LV EF without indications for MR surgery, these markers were informative in a regard to the prognosis [18, 25].

According to the results of the study published in 2014, the stress test has prognostic value: 884 patients with severe MR and preserved LV EF were examined. Those patients who did not reach 85 % of necessary load had worse prognosis. In 576 pa-

Table 2. Primary MR disease stages

Stage	Definition	Hemodynamic changes	Symptoms
A	Risk of MR	No	No data
B	MR progression	- Moderate enlargement of LA - No LV enlargement - Normal pressure in lung artery	No data
C	Asymptomatic severe MR	- Moderate or severe LA enlargement - LV enlargement - PH is present in resting state or during: physical activity — C1: LV EF > 60 % and LVID < 40 mm — C2: LV EF ≤ 60 % and LVID ≥ 40 mm	No data
D	Symptomatic severe MR	Moderate or severe LA enlargement LV enlargement PH	Reduced exercise tolerance Dyspnea during physical activity




Fig. 1. Echo of the patient with severe MR before surgery

tients who performed over 100% load, a refusal from MV surgery was not associated with a poor prognosis for at least five years [26].

Step 5. What are the indications for surgical treatment of severe primary MC in asymptomatic patients?

The latest 2021 Clinical Guidelines for the Management of Valvular Heart Disease of the European Society of Cardiology and Cardiothoracic Surgeons state that if the probability of successful MV repair is over 95% and the estimated mortality of planned surgery is less than 1%, surgical treatment should be performed in patients severe MR. It is especially important in the presence of PH, LV enlargement, LV EF decrease less than 60% [27, 28]. According to above-mentioned guidelines, there should be very strong reasons not to perform surgery in these patients. One of such reasons can be insufficient experience of the surgical team, inability to guarantee the success of MV repair.

Summarizing the information above, the patient should undergo surgical treatment in case when severe MR is detected and there is no need to wait for the development of LV dysfunction and progression of clinical symptoms, and it is important to have an experienced surgical team that can offer wide range of surgeries on MV [29, 30].

Step 6. Cardiologist and the cardiac surgeon should inform patient on which MV surgery is and surgical incisions are planned.

Possible surgical approach options for surgical treatment of MR include total sternotomy, partial sternotomy, and anterolateral thoracotomy. There are many variants of MV repair and its combinations, and implantation of artificial heart valves is performed using both biological and mechanical prostheses. MV repair is preferable to mitral prosthesis in

patients with isolated primary MR [4, 18], especially when using a mini-access.

Step 7. The key one, concerning the residual (return) MR and LV EF. Residual MR occurs infrequently, mainly after anterior MV leaflet repair, or the repair without using MM ring. The lower postoperative EF is, the worse are the outcomes [28].

Discussion

In the presented clinical case the patient underwent an echocardiography (Echo) (Fig. 1): the MV leaflets had myxomatous degeneration, there were anterior and posterior MV leaflets prolapse, dilation of the left LA, LV, MV fibrous ring. LV EF was 58%, systolic pulmonary artery pressure (SPAP) was 39 mm Hg. Color flow doppler indicated the presence of eccentrically directed heavy MR flow. ERO—0.45 cm², RV—70 ml were calculated, which quantitatively confirmed the severity of the detected pathology.

According to the Echo results, the patient had severe asymptomatic MR in the background of Barlow disease, with hemodynamic overload of the left heart chambers, which has been going on all these years without affecting the patient's quality of life. Obviously, the had stage C, progressing MR, waiting for the appearance of clinical manifestation of the disease (stage D) is unacceptable, as it will worsen the patient's life prognosis and will not lead to the improvement of the condition after MV surgery, if it is postponed again (see Table 1).

On this basis, the patient was recommended to undergo MV repair with the installation of the support ring and it was explained that in case of unsatisfactory results, a prosthetic MV will be needed. Effective correction of the defect is evaluated intraoperatively, and if the MR persists, the patient is reoperated.




Fig. 2. ECHO of the patient after the surgery

In this clinical case the dilated MV fibrous ring was narrowed, it resulted in optimal coaptation of excess MV leaflet surfaces, providing an extended zone of contact between the anterior and posterior leaflets. One week after, by the time of discharge, due to the absence of volume overload, the size of LV and LV decreased, there were no residual MR, systolic anterior motion (SAM)-syndrome, EF was normal (Fig. 2). The patient was discharged in good condition.

Conclusion

The management of patients with severe primary MR should be performed in accordance with the current guidelines on valve diseases.

It is simple and clear to follow the algorithm when there are clinical manifestations of the disease and

LV dysfunction; more difficult—when there are no symptoms. However, according to the 2021 guidelines, the earlier surgery is associated with better results.

The key point of the diagnosis is accurate Echo data. In addition, the role of biomarkers, stress test, and LV Strain is important.

The decision-making team regarding surgical treatment of MR should discuss all cases of severe primary MR, recommend the best time for surgery, suggest advanced valve repair techniques, and present their own experience and success in this direction.

Conflict of interest: None declared.

References

- Maslow A. Mitral valve repair: An echocardiographic review: Part 1. *J Cardiothorac Vasc Anesth*. 2015;29(1):156–177.
- Garbi M, Monaghan MJ. Quantitative mitral valve anatomy and pathology. *Echo Res Pract*. [2015] 2:R63–72. doi: 10.1530/ERP-15-0008.
- Uretsky S., Gillam L., Lang R. et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. *J Am Coll Cardiol* 2015; 65: 1078–88. DOI: 10.1016/j.jacc.2014.12.047.
- Two and Three-Dimensional Echocardiography in Primary Mitral Regurgitation: practical hints to optimize the surgical planning. *Front. Cardiovasc. Med.*, 08 July 2021. Sec. Cardiovascular Imaging. <https://doi.org/10.3389/fcvm.2021.706165>.
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021; 143:e72.
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2022; 43:561.
- Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. [2013] 14:611–44. doi: 10.1093/ehjci/jet105.
- Eirini Apostolidou, Andrew D Maslow, and Athena Poppas. Primary mitral valve regurgitation: Update and review. *Glob Cardiol Sci Pract*. 2017 Mar 31;2017(1):e201703. doi: 10.21542/gcsp.2017.3.PMID: 31139637.
- Dzemeshchevich S.L., Stivenston L.U. The diseases of mitral valve: function, diagnostics, treatment. Second revised ed. «GEOTAR-Media», 2015. Russian.

10. Nishimura R, Vahanian A, et al. Mitral valve disease- current management and future challenges. *Lancet*. 2016;387:1324–1334.
11. Cimino S, Guarracino F, Valenti V, Frati G, Sciarretta S, Miraldi F, et al. Echocardiography and correction of mitral regurgitation: an unbreakable link. *Cardiology*. 2020; 145:110–20. doi: 10.1159/000504248.
12. Maslow A. Mitral valve repair: An echocardiographic review: Part 2. *J Cardiothorac Vasc Anesth*. 2015;29(2):439–471.
13. El Sabbagh A, Reddy YNV, Nishimura RA. Mitral valve regurgitation in the contemporary era: insights into diagnosis, management, and future directions. *JACC Cardiovasc Imaging*. 2018; 11:628–43. doi: 10.1016/j.jcmg.2018.01.009.
14. Cimino S, Guarracino F, Valenti V, Frati G, Sciarretta S, Miraldi F, et al. Echocardiography and correction of mitral regurgitation: an unbreakable link. *Cardiology*. 2020; 145:110–20. doi: 10.1159/000504248
15. Enriquez-Sarano M., Suri R.M., Clavel M.A., et al. Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation. *J Thorac Cardiovasc Surg*. 2015; 150:50. doi: 10.1016/j.jtcvs.2015.04.009
16. Naji P, Griffin B, et al. Predictors of long- term outcomes in patients with significant myxomatous mitral regurgitation undergoing exercise echocardiography. *Circulation*. 2014;129(12):1310–1319.
17. Magne J, Mahjoub H, Dulgheru R, Pibarot P, Pierard LA, Lancellotti P. Left ventricular contractile reserve in asymptomatic primary mitral regurgitation. *Eur Heart J*. 2014; 35:1608–1616. doi: 10.1093/eurheartj/ehx345
18. Quintana E, Suri RM, Thalji NM, et al. Left ventricular dysfunction after mitral valve repair--the fallacy of «normal» preoperative myocardial function. *J Thorac Cardiovasc Surg*. 2014; 148:2752.
19. Suri RM, Vanoverschelde JL, Grigioni F, et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. *JAMA*. 2013; 310:609.
20. Murashita T., Okada Y., Kanemitsu H., et al. The impact of preoperative and postoperative pulmonary hypertension on long-term surgical outcome after mitral valve repair for degenerative mitral regurgitation. *Ann Thorac Cardiovasc Surg*. 2015; 21:53. doi: 10.5761/atcs.0a.13-00364.
21. The clinical guidelines for mitral regurgitation of cardiovascular Surgeons of Russia, VNOK 2016. Russian (Клинические рекомендации по митральной недостаточности Ассоциации Сердечно-сосудистых хирургов России, ВНОК, 2016).
22. Bergler J., Gyongyosi M., Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. *Can J Cardiol*. 2014; 30:1027. DOI: 10.1016/j.cjca.2014.07.014
23. Alashi A, Mentias A, et al. Synergistic utility of brain natriuretic peptide and left ventricular global longitudinal strain in asymptomatic patients with significant primary mitral regurgitation and preserved systolic function undergoing mitral valve surgery. *Circ Cardiovasc Imaging*. 2016;9:e004451.
24. Pastore MC, Mandoli GE, Dokollari A, Bisleri G, D'Ascenzi F, Santoro C, et al. Speckle tracking echocardiography in primary mitral regurgitation: should we reconsider the time for intervention? *Heart Fail Rev*. 2021. doi: 10.1007/s10741-021-10100-1. [Epub ahead of print].
25. Kim HM, Cho GY, Hwang IC, Choi HM, Park JB, Yoon YE, et al. Myocardial strain in prediction of outcomes after surgery for severe mitral regurgitation. *JACC Cardiovasc Imaging*. 2018 11:1235–44. doi: 10.1016/j.jcmg.2018.03.016
26. Baumgartner H., Falk V., Bax J.J., et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017; 38:2739. doi: 10.1093/eurheartj/ehx391
27. Vassileva C.M., Mishkel G., McNeely C., et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. *Circulation*. 2013; 127:1870. DOI: 10.1161/CIRCULATIONAHA.113.002200
28. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of mitral valve repair for regurgitation due to leaflet prolapse. *J Am Coll Cardiol*. 2019. 74:1044–53. doi: 10.1016/j.jacc.2019.06.052.
29. Kang DH, Park SJ, Sun BJ, Cho EJ, Kim DH, Yun SC, et al. Early surgery versus conventional treatment for asymptomatic severe mitral regurgitation: a propensity analysis. *J Am Coll Cardiol*. 2014;63(22):2398–407.
30. Goldstone AB, Patrick WL, Cohen JE, Aribena CN, Popat R, Woo YJ. Early surgical intervention or watchful waiting for management of asymptomatic mitral regurgitation: a systematic review and meta-analysis. *Ann Cardiothorac Surg*. 2015;4(3):220–9.